Organogenesis Holdings Stock-Based Compensation Growth & History (ORGO)
Organogenesis Holdings's stock-based compensation was $13.3M for fiscal 2025.
View full Organogenesis Holdings company overviewOrganogenesis Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.3M | $2.7M | +25.71% |
| 2024 | 2024-12-31 | $10.6M | $1.6M | +17.59% |
| 2023 | 2023-12-31 | $9.0M | $2.4M | +37.30% |
| 2022 | 2022-12-31 | $6.6M | $2.7M | +69.57% |
| 2021 | 2021-12-31 | $3.9M | $2.2M | +132.63% |
| 2020 | 2020-12-31 | $1.7M | $725,000 | +77.46% |
| 2019 | 2019-12-31 | $936,000 | −$139,000 | −12.93% |
| 2018 | 2018-12-31 | $1.1M | $156,000 | +16.97% |
| 2017 | 2017-12-31 | $919,000 | $446,000 | +94.29% |
| 2016 | 2016-12-31 | $473,000 | — | — |
Organogenesis Holdings quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.1M | $510,000 | +20.06% |
| Q1 2026 | 2026-03-31 | $3.6M | $269,000 | +7.99% |
| Q4 2025 | 2025-12-31 | $4.3M | $1.4M | +49.57% |
| Q3 2025 | 2025-09-30 | $3.1M | $353,000 | +13.02% |
| Q2 2025 | 2025-06-30 | $2.5M | −$26,000 | −1.01% |
| Q1 2025 | 2025-03-31 | $3.4M | $960,000 | +39.88% |
| Q4 2024 | 2024-12-31 | $2.9M | $525,000 | +22.19% |
| Q3 2024 | 2024-09-30 | $2.7M | $295,000 | +12.21% |
| Q2 2024 | 2024-06-30 | $2.6M | $269,000 | +11.70% |
| Q1 2024 | 2024-03-31 | $2.4M | $493,000 | +25.76% |
| Q4 2023 | 2023-12-31 | $2.4M | $511,000 | +27.55% |
| Q3 2023 | 2023-09-30 | $2.4M | $715,000 | +42.01% |
| Q2 2023 | 2023-06-30 | $2.3M | $607,000 | +35.87% |
| Q1 2023 | 2023-03-31 | $1.9M | $611,000 | +46.89% |
| Q4 2022 | 2022-12-31 | $1.9M | $772,000 | +71.28% |
| Q3 2022 | 2022-09-30 | $1.7M | $661,000 | +63.50% |
| Q2 2022 | 2022-06-30 | $1.7M | $650,000 | +62.38% |
| Q1 2022 | 2022-03-31 | $1.3M | $605,000 | +86.68% |
| Q4 2021 | 2021-12-31 | $1.1M | $586,000 | +117.91% |
| Q3 2021 | 2021-09-30 | $1.0M | $555,000 | +114.20% |
| Q2 2021 | 2021-06-30 | $1.0M | $573,000 | +122.17% |
| Q1 2021 | 2021-03-31 | $698,000 | $489,000 | +233.97% |
| Q4 2020 | 2020-12-31 | $497,000 | $261,000 | +110.59% |
| Q3 2020 | 2020-09-30 | $486,000 | $244,000 | +100.83% |
| Q2 2020 | 2020-06-30 | $469,000 | $235,000 | +100.43% |
| Q1 2020 | 2020-03-31 | $209,000 | −$15,000 | −6.70% |
| Q4 2019 | 2019-12-31 | $236,000 | −$19,000 | −7.45% |
| Q3 2019 | 2019-09-30 | $242,000 | −$10,000 | −3.97% |
| Q2 2019 | 2019-06-30 | $234,000 | −$17,000 | −6.77% |
| Q1 2019 | 2019-03-31 | $224,000 | −$93,000 | −29.34% |
| Q4 2018 | 2018-12-31 | $255,000 | — | — |
| Q3 2018 | 2018-09-30 | $252,000 | — | — |
| Q2 2018 | 2018-06-30 | $251,000 | — | — |
| Q1 2018 | 2018-03-31 | $317,000 | — | — |
Organogenesis Holdings stock-based compensation trends
Over the last five fiscal years, Organogenesis Holdings's stock-based compensation increased from $1.7M to $13.3M, a change of $11.6M. The latest reported quarter, Q2 2026, shows $3.1M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Organogenesis Holdings source filings ↗